Articles by Abby Proch

  1. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

    Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

  2. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

  3. 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint 8/21/2026

    Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.

  4. Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial 8/20/2026

    Viral stock can make or break a norovirus challenge study. Cocrystal Pharma's Sam Lee explains why inoculum quality, infectivity, and availability matter.

  5. Rare Disease Study Gets A Boost From Crowdsourced Patient Reported Data 8/18/2026

    Jen A. Levitt, MD, explains how crowdsourced patient-reported data and AI tools can compress rare disease research timelines and surface new signals.

  6. The Patient Advocacy Strategy Behind Skyhawk's Rapid Enrollment 8/13/2026

    Skyhawk’s patient-first approach shows how advocacy partnerships, site engagement, and operational quality can accelerate enrollment without losing focus on patients.

  7. What The FDA's Latest Move On Psychedelics Means For Non-Hallucinogenic Drug Sponsors 8/13/2026

    Taking another angle to the FDA focus on psychedelic research, Enveric Biosciences CEO Joseph Tucker, Ph.D., explores what the FDA’s moves mean for non-hallucinogenic drug sponsors.

  8. What The FDA's Psychedelic Drug Focus Means For Classic Psychedelic Development 8/13/2026

    Complementing an interview with Enveric Bioscience's Joseph Tucker, Ph.D., this Q&A explores Josh Hardman's thoughts on what FDA’s psychedelic focus could mean for classic psychedelic development.

  9. How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy 8/12/2026

    Opus Genetics shares how FDA alignment yielded a clearer path for its ultra-rare LCA5 gene therapy, shaping trial design, evidence generation, and operations.

  10. What It Takes To Validate A Biomarker For Real-World, Post-Transplant Care 8/7/2026

    Yelena Bushman, MBA, VP of cell therapy and transplant at CareDx, discusses the operational challenges of validating biomarkers for post-transplant care.